85-08-5

Usage

Uses

Used in Pharmaceutical Industry:
(2-methyl-1-naphthyl)acetic acid is used as a pharmaceutical agent for its potential anti-inflammatory and anti-tumor properties. It may be employed in the development of drugs targeting inflammation and cancer treatment.
Used in Agricultural Industry:
(2-methyl-1-naphthyl)acetic acid is used as a growth regulator in plants, potentially enhancing crop yield and quality. Its application in agriculture may contribute to more efficient and sustainable farming practices.
Further research is needed to fully understand the uses and effects of (2-methyl-1-naphthyl)acetic acid in various fields, including medicine and agriculture.

InChI:InChI=1/C13H12O2/c1-9-6-7-10-4-2-3-5-11(10)12(9)8-13(14)15/h2-7H,8H2,1H3,(H,14,15)

Upstream product

• 1590-08-5 2-methyl-1-tetralone 
• 5764-82-9 bromo(2-ethoxy-2-oxoethyl)zinc 
• 86-87-3 naphth-1-yl acetic acid 
• 124-40-3 dimethyl amine 
• 124-38-9 carbon dioxide 
• 1140-52-9 α-Naphthylessigsaeure-N.N-dimethylamid 
• 529-33-9 1,2,3,4-Tetrahydro-1-naphthol 
• 3918-24-9 (5,6,7,8-tetrahydro-[1]naphthyl)-acetic acid dimethylamide 
• 69815-53-8 (2-methyl-1-napthyl)acetonitrile 
• 100-39-0 benzyl bromide 
• 40482-44-8 4S-(-)-isopropyl-2-oxazolidinone 
• 581-96-4 2-naphthylacetic acid 
• 1592-38-7 2-Naphthalenemethanol 

Relevant academic research and scientific papers

Aromatic Claisen Rearrangements of Benzyl Ketene Acetals: Conversion of Benzylic Alcohols to (ortho-Tolyl)acetates

Claisen rearrangements of benzyl vinyl ethers are much less facile than those of aliphatic allyl vinyl ethers, and their synthetic utility has remained relatively unexplored. A one-pot procedure is reported for the generation and Claisen rearrangement of benzyl vinyl ethers that contain an activating α-alkoxy substituent on the vinyl group. A [3,3]-sigmatropic mechanism was supported by trapping of the intermediate isotoluene in an intramolecular Alder–ene reaction.

Arylsulfonamide ethers, and methods of use thereof

Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.

Src family SH2 domain inhibitors

This invention relates to compounds of formula (1): wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands.